A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer

Effect of neoadjuvant chemotherapy using paclitaxel combined with carboplatin on advanced non-small cell lung cancer

“…Patients given preoperative neoadjuvant chemotherapy in our study had a two year survival rate of 25%, which is better than the report of patients with supraclavicular receiving induction chemotherapy (two year survival rate of 16.7%) and worse than III stage patients receiving induction chemotherapy (two year survival rate of 43.9%) [7] . Thus, consistent with other studies [8][9][10] , preoperative neoadjuvant chemotherapy using a combination of paclitaxel and carboplatin effectively improved the prognosis of local advanced NSCLC patients.…”

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study

“…An overall clinical response of 70% was achieved [24]. Similarly, in two Italian phase II studies conducted by Migliorino et al [25] and Cappuzzo et al [26], activity and feasibility of a 3-week schedule of gemcitabine/cisplatin as induction therapy was evaluated in patients with stage IIIA/N2 and select stage IIIB NSCLC. In both studies there was an overall response rate of approximately 60%, three percent of which was pathological complete response.…”

A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer

“…In our unresectable patients, we observed a 3-year OS of 17% that was identical to that reported by Albain et al in a phase II Southwest Oncology Group (SWOG) study using concurrent chemoradiotherapy with cisplatin and etoposide without induction chemotherapy [5] and somewhat lower than the one reported by Vokes et al in their three-arm randomized Cancer and Leukemia Group B (CALGB) study of cisplatin-based induction followed by the same cisplatin-based chemoradiotherapy (19-28%) [20]. Phase II trials of cisplatin and gemcitabine in resectable NSCLC have produced encouraging antitumor activity with responses rates of 40-70% [20,[35][36][37]42]. In a phase II trial of induction cisplatin and gemcitabine conducted by Migliorino et al, a response rate of 35% was observed in stage IIIB patients [35].…”

“…Phase II trials of cisplatin and gemcitabine in resectable NSCLC have produced encouraging antitumor activity with responses rates of 40-70% [20,[35][36][37]42]. In a phase II trial of induction cisplatin and gemcitabine conducted by Migliorino et al, a response rate of 35% was observed in stage IIIB patients [35].…”

“…Gemcitabine, a pyrimidine antimetabolite, has been widely used for the treatment of advanced NSCLC, alone or in combination regimens. Cisplatin and gemcitabine has been shown to be active as induction chemotherapy in locally advanced NSCLC [20,[35][36][37], whereas the combination of carboplatin and gemcitabine is an active and well tolerated doublet in advanced NSCLC [38,39]. We currently report mature results of our phase I/II trial with induction carboplatin and gemcitabine followed by concurrent chemoradiotherapy with vinorelbine and paclitaxel, followed by surgery in resectable tumors, in patients with stage III NSCLC.…”